Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2011-01-11
2011-01-11
Berch, Mark L (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
Reexamination Certificate
active
07868011
ABSTRACT:
The present invention provides methods for suppressing autoimmunity in a patient in need of treatment for systemic lupus erythematosus by administering to the patient an effective amount of methyl 4-(Adenin-9-yl)-2-hydroxybutanoate or pharmaceutically acceptable salts thereof. In some embodiments, the claimed methods include co-administering an effective amount of an immunosuppressant.
REFERENCES:
patent: 5137876 (1992-08-01), MacCoss et al.
patent: 5593990 (1997-01-01), D'Amato
patent: 5629327 (1997-05-01), D'Amato
patent: 5641783 (1997-06-01), Klein et al.
patent: 5668173 (1997-09-01), Garrow
patent: 5686102 (1997-11-01), Gross et al.
patent: 5712291 (1998-01-01), D'Amato
patent: 5736154 (1998-04-01), Fuisz
patent: 5741511 (1998-04-01), Lee et al.
patent: 5756466 (1998-05-01), Bemis et al.
patent: 5854023 (1998-12-01), Hillman et al.
patent: 5869305 (1999-02-01), Samulski et al.
patent: 5886039 (1999-03-01), Kock et al.
patent: 5888767 (1999-03-01), Dropulić et al.
patent: 5941868 (1999-08-01), Kaplan et al.
patent: 5962274 (1999-10-01), Parks
patent: 6020337 (2000-02-01), Leigh et al.
patent: 6066467 (2000-05-01), Xu et al.
patent: 6127381 (2000-10-01), Basu et al.
patent: 6133274 (2000-10-01), Underiner et al.
patent: 6197774 (2001-03-01), Yamada et al.
patent: 6197801 (2001-03-01), Lin
patent: 6203818 (2001-03-01), Vester
patent: 6210686 (2001-04-01), Bell et al.
patent: 6258374 (2001-07-01), Friess et al.
patent: 6274170 (2001-08-01), Heibel et al.
patent: 6323188 (2001-11-01), Weissman
patent: 6337317 (2002-01-01), Hancock et al.
patent: 6353003 (2002-03-01), Anderson
patent: 6361800 (2002-03-01), Cooper et al.
patent: 6429212 (2002-08-01), Hasimoto
patent: 6455528 (2002-09-01), Adachi et al.
patent: 6492370 (2002-12-01), Mita et al.
patent: 6541482 (2003-04-01), Edwards et al.
patent: 7196093 (2007-03-01), Yuan
patent: 2002/0044919 (2002-04-01), Yu
patent: 2004/0010007 (2004-01-01), Dellaria et al.
patent: 2005/0182075 (2005-08-01), Yuan
patent: 2007/0129386 (2007-06-01), Yuan
patent: 2007/0207172 (2007-09-01), Yuan
patent: 1220148 (1987-04-01), None
patent: 3435491 (1983-09-01), None
patent: 1330704 (1973-09-01), None
patent: WO-95/00514 (1995-01-01), None
patent: WO-99/26660 (1999-06-01), None
patent: WO-00/64479 (2000-11-01), None
patent: WO-2005/009334 (2005-02-01), None
Eisenberg, Journal of Autoimmunity 32 (2009) 223-230.
Dallos and Kovacs, Bratisl Lek Listy (2005) 106(2):55-62.
Grassegger et al., British Journal of Dermatology (1998) 139(4):639-648.
Khalil and O'Connor, CMAJ (2004) 171(2):153-160.
Raghu et al., New England Journal of Medicine (2004) 350:125-133.
Wickelgren, Science (2004) 306:596-599.
Association of the British Pharmaceutical Industry, “Target Crohn's and Colitis: Inflammatory Bowel Disease and the Pharmaceutical Industry- Future Medicines in the Development Pipeline” at <http://www.abpi.org.uk> (visited Feb. 4, 2003).
Auerbach and Auerbach, “Angiogenesis Inhibition: A Review” Pharmacol. Ther. 63:265-311 (1994).
Bao, L. et al., “The Critical Role of IL-12p40 in Initiating, Enhancing, and Perpetuating Pathogenic Events in Murine Experimental Autoimmune Neuritis” [Abstract] at <http://www.brainpathology.com> (visited Feb. 4, 2003).
Bartlett et al., “CAVEAT: A Program to Facilitate the Strucure-Derived Design of Biologically Active Molecules”in Molecular Recognition in Chemical and Biological Problems, Special Pub., Royal Chem. Soc. 78:182-196 (1989).
Bohm, “The Computer Program LUDI: A New Method for the De Novo Design of Enzyme Inhibitors” J. Comp. Aid. Molec. Design 6:61-78 (1992).
Brooks et al., “CHARMM: A Program for Macromolecular Energy, Minimization, and Dynamics Calculations” J Comp. Chem. 4(2):187-217 (1983).
Cerino, V., “UNMC Dentistry Researchers Receive $209,000 Grant to Study Role of Protein in Multiple Sclerosis” at <http://www.unmc.edu/News/petro.htm> (visited Feb. 4, 2003).
Chem. Abstr. 1972:514811.
Cohen et al., J. Med. Chem. 33:883-894 (1990).
Commission of Biochemical Nomenclature, “IUPAC-IUB Commission on Biochemical Nomenclature Symbols for Amino-Acid Derivatives and Peptides Recommendations (1971)” Biochemistry 11:1726-1732 (1972).
Coulter-Karis and Hershfield, “Sequence of Full Length cDNA for Human S-Adenosylhomocysteine Hydrolase” Ann. Hum. Genet. 53(2):169-175 (1989).
Dictionary of Biochemistry and Molecular Biology, Second Edition, John Wiley & Sons (1989) p. 417.
Dvorakova et al., Collection of Czechoslovak Chemical Communications (1993) 58(3):629-648.
Gewolb, J., “New Diabetes Gene Found” at <http://bric.postech.ac.kr/science/97now/01—1now/010130a.html> (visited Feb. 4, 2003).
Goodford, “A Computational Procedure for Determining Energetically Favorable Binding Sites on Biologically Important Macromolecules” J. Med. Chem. 28:849-857 (1985).
Goodman and Gilman,The Pharmacological Basis of Therapeutics, (9thed.), McGraw-Hill pp. 1294-1304 (1996).
Goodsell et al., “Automated Docking of Substrates to Proteins by Simulated Annealing” Proteins: Structure, Function and Genetics 8:195-202 (1990).
't Hart et al., Drug Discovery Today (2004) 9(12):517-524.
Holy et al., “Structure-Activity Studies on Open-Chain Analogues of Nucleosides: Inhibition of S-Adenosyl-L-Homocysteine Hydrolase and Antiviral Activity” Coll. Czechoslovak Chem. Commun. 50:262-279 (1985).
Holy, Coll. Czech. Chem. Commun. 43:3444-3464 (1978).
Hopfinger et al.,In Concepts and Applications of Molecular SimilarityJohnson and Maggiora (eds.), Wiley (1990).
International Search Report for PCT/US04/11229, mailed on Aug. 17, 2005, 4 pages.
Kirkman, R., “Protein Design Labs (PDLI) Begins Phase I Clinical Trial of Smart Anti-IL-12 Antibody” at <http://www.biospace.com
ews—story.cfm?storyID=9223720&full=1> (visited Feb. 4, 2003).
Klebe, G., “Recent Developments in Structure-Based Drug Design” J. Mol. Med. 78:269-281 (2000).
Kuntz et al., “A Geometric Approach to Macromolecule-Ligand Interactions” J. Mol. Biol. 161:269-288 (1982).
Maignan et al., Curr. Top. Med. Chem. 1:161-174 (2001).
Marshall, Ann. Ref. Pharmacol. Toxicol. 27:193 (1987).
Martin, “3D Database Searching in Drug Design” J. Med. Chem. 35(12):2145-2154 (1992).
Mayer et al., J. Comp. Aided Molec. Design 1:3-16 (1987).
Merta, A. et al., “S-Adenosyl-L-Homocysteine Hydrolase from Mouse Leukemic Cells: Isolation and Properties” Coll. Czech. Chem. Commun. 48:2701-2708 (1983).
Miranker et al., “Functionality Maps of Binding Sites: A Multiple Copy Simultaneous Search Method” Proteins: Structure, Function and Genetics 11:29-34 (1991).
National Institute of Health, “Understanding Autoimmune Disease” at <http://www.niaid.nih.gov/publications/autoimmune/autoimmune.htm> (visited Apr. 10, 2003).
Navia et al., Curr. Opin. Struc. Biol. 2:202-210 (1991).
Nishibata et al., “Automatic Creation of Drug Candidate Structures Based on Receptor Stucture. Starting Point for Artificial Lead Generation” Tetrahedron 47(43):8985-8990 (1991).
O'Reilly, M., “The Preclinical Evaluation of Angiogenesis Inhibitors” Investigational New Drugs 15:5-13 (1997).
Rao and Segal in: Methods in Molecular Science, vol. 102, Autoimmunity: Methods and Protocols, Perl (ed.), Human Press Inc. (2004) Ch. 19, pp. 363-375.
Schanche et al., “The Effect of Aliphatic Adenine Analogues on S-Adenosylhomocysteine and S-Adenosylhomocysteine Hydrolase in Intact Rat Hepatocytes” Molecular Pharmacology 26:553-558 (1984).
Seshadri et al., “Plasma Homocysteine As a Risk Factor for Dementia and Alzheimer's Disease” N. Eng. J. Med. 46:476-483 (2002).
Simpson et al., “Spectrophotometric Determination of Lymphocyte Mediated Sheep Red Blood Cell Hemolysis In Vitro” J. Immunol. Methods 21:159-165 (1978).
Steinman, L., “Multiple Scleros
Berch Mark L
General Atomics
Morrison & Foerster / LLP
LandOfFree
Use of reversible inhibitors of S-adenosyl-L-homocysteine... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Use of reversible inhibitors of S-adenosyl-L-homocysteine..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Use of reversible inhibitors of S-adenosyl-L-homocysteine... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2712160